USS Investment Management Ltd Boosts Stock Holdings in Bristol Myers Squibb Company $BMY

USS Investment Management Ltd grew its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 5.6% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 382,894 shares of the biopharmaceutical company’s stock after purchasing an additional 20,383 shares during the quarter. USS Investment Management Ltd’s holdings in Bristol Myers Squibb were worth $23,221,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the business. Brighton Jones LLC raised its stake in Bristol Myers Squibb by 33.4% in the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after buying an additional 4,935 shares in the last quarter. Sivia Capital Partners LLC lifted its holdings in Bristol Myers Squibb by 59.4% during the second quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock worth $346,000 after buying an additional 2,786 shares during the period. United Bank boosted its position in Bristol Myers Squibb by 15.0% during the 2nd quarter. United Bank now owns 25,148 shares of the biopharmaceutical company’s stock valued at $1,164,000 after acquiring an additional 3,277 shares in the last quarter. Marshall Wace LLP bought a new stake in Bristol Myers Squibb during the 2nd quarter valued at $221,000. Finally, Nebula Research & Development LLC purchased a new position in shares of Bristol Myers Squibb in the 2nd quarter valued at $405,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

BMY has been the subject of a number of analyst reports. Guggenheim restated a “buy” rating and set a $72.00 price objective on shares of Bristol Myers Squibb in a research note on Wednesday, April 8th. UBS Group reiterated a “buy” rating on shares of Bristol Myers Squibb in a research note on Thursday, May 28th. Citigroup reiterated a “neutral” rating on shares of Bristol Myers Squibb in a report on Friday, May 1st. Bank of America decreased their price target on shares of Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating for the company in a research report on Thursday, April 9th. Finally, Wall Street Zen upgraded shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday. Eight research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Bristol Myers Squibb currently has a consensus rating of “Hold” and an average target price of $61.31.

Bristol Myers Squibb Stock Performance

Shares of BMY stock opened at $57.63 on Wednesday. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $62.89. The business’s fifty day simple moving average is $57.00 and its 200-day simple moving average is $57.41. The company has a current ratio of 1.42, a quick ratio of 1.28 and a debt-to-equity ratio of 2.10. The company has a market cap of $117.68 billion, a PE ratio of 16.19, a PEG ratio of 0.17 and a beta of 0.24.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, topping analysts’ consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The firm had revenue of $11.49 billion during the quarter, compared to analysts’ expectations of $10.93 billion. During the same quarter last year, the firm earned $1.80 EPS. The business’s quarterly revenue was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Analysts expect that Bristol Myers Squibb Company will post 6.32 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 4.4%. The ex-dividend date of this dividend is Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 70.79%.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Unusual options activity turned constructive, with investors buying 53,552 call options on Bristol Myers Squibb, roughly 135% above the stock’s normal call volume. That suggests traders are positioning for more upside.
• Positive Sentiment: Several recent writeups highlighted Bristol Myers Squibb as a top value and momentum name, reinforcing the view that the stock may remain attractive to investors looking for defensive healthcare exposure and earnings stability. Article on BMY as a top value stock
• Neutral Sentiment: Market commentary also pointed to BMY as a stock that recently outperformed the broader market, which may be supporting near-term trading interest but is not a major new fundamental catalyst. Article on BMY exceeding market returns
• Negative Sentiment: One healthcare article raised concern about potential risk from proposed Medicare drug price negotiation updates, which could pressure long-term pricing and margins for large pharma names like Bristol Myers Squibb. Article on Medicare drug price negotiation risk

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.